stockrow
Friday 6 November 2026
Export IRMD’s income statement to Excel — free account
iRadimed Corporation
IRMD Healthcare Medical Devices
iRadimed Corporation’s revenue for fiscal 2025 (year ended December 2025) was $83.8 million, up 14.4% from fiscal 2024.
- Revenue
- +14.2%
- EPS
- +15.9%
- Free cash flow
- +18.6%
Quarter to September 2026, against a year earlier
86.17
0.63
+0.74%
Follow IRMD
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
54.96 | 51.75 | 52.51 | 45.62 |
P/S ratio |
14.77 | 14.26 | 14.15 | 12.34 | |
P/FCF ratio |
79.57 | 53.50 | 51.82 | 44.75 | |
P/Operating CF |
208.96 | 148.43 | 205.66 | 157.57 | |
P/B ratio |
13.08 | 12.49 | 12.01 | 10.36 | |
Price to Tangible BV |
13.57 | 12.92 | 12.43 | 10.70 | |
EV/Sales |
14.16 | 13.61 | 13.47 | 11.63 | |
EV/EBITDA |
43.44 | 39.96 | 39.84 | 34.05 | |
EV/Operating CF |
47.56 | 40.56 | 42.84 | 38.28 | |
EV/FCF |
76.28 | 51.05 | 49.31 | 42.18 | |
Quick Ratio |
6.37 | 5.76 | 7.89 | 7.46 | |
Current Ratio |
7.98 | 7.13 | 9.46 | 8.99 | |
Net Debt/EBITDA |
(6.84) | (7.33) | (8.69) | (7.40) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.81 | 0.80 | 0.78 | 0.76 | |
Operating CF/Net income |
0.92 | 1.42 | 1.14 | 1.08 | |
Capex/Depreciation |
(1.09) | (1.03) | (1.08) | (0.51) | |
Research and Development Expense of Revenue |
3.52% | 4.35% | 3.21% | 3.62% | |
Selling, General and Administrative Expense of Revenue |
40.27% | 39.22% | 39.64% | 39.01% | |
Intangible Assets out of Total Assets |
0.03 | 0.03 | 0.03 | 0.03 | |
Share Based Compensation of Revenue |
3.07% | 3.11% | 3.94% | 3.21% | |
Graham Net Nets |
0.05 | 0.06 | 0.06 | 0.07 | |
Graham Number |
17.21 | 17.96 | 18.05 | 18.82 | |
Earnings Yield |
1.82% | 1.93% | 1.90% | 2.19% | |
Free Cash Flow Yield |
1.26% | 1.87% | 1.93% | 2.23% | |
Revenue per Share |
1.78 | 1.72 | 1.60 | 1.89 | |
Operating CF per Share |
0.47 | 0.65 | 0.46 | 0.55 | |
Capex per Share |
(0.03) | (0.04) | (0.03) | (0.02) | |
Free Cash Flow per Share |
0.43 | 0.61 | 0.43 | 0.53 | |
Cash per Share |
4.02 | 4.41 | 4.62 | 4.95 | |
Shareholders Equity per Share |
7.44 | 7.71 | 7.96 | 8.33 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
7.44 | 7.71 | 7.96 | 8.33 | |
Free Cash Flow |
5.51 | 7.82 | 5.50 | 6.79 | |
Working Capital |
71.02 | 74.30 | 77.56 | 82.48 | |
Capital Expenditures |
(0.42) | (0.47) | (0.44) | (0.21) | |
Net Current Asset Value |
67.05 | 70.55 | 73.50 | 78.18 | |
EV/EBIT |
45.38 | 42.00 | 42.19 | 36.01 | |
Capex to Sales |
0.02 | 0.02 | 0.02 | 0.01 | |
Price to Operating Income |
47.33 | 44.02 | 44.33 | 38.20 | |
| Other line items | |||||
Average Receivables |
12.11 | 13.06 | 12.06 | 13.77 | |
Average Payables |
1.86 | 2.39 | 1.88 | 2.38 | |
Average Inventory |
11.01 | 11.22 | 11.73 | 12.61 | |
Average Assets |
103.55 | 108.06 | 110.71 | 117.90 | |
Average Common Equity |
90.72 | 94.28 | 98.02 | 102.40 |
Columns are period end dates · fundamentals updated 6 Nov 2026